Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional Study

Sharon C. M. Essink, Inge M. Zomerdijk, Sabine M. J. M. Straus, Helga Gardarsdottir and Marie L. Bruin ()
Additional contact information
Sharon C. M. Essink: Utrecht University
Inge M. Zomerdijk: Medicines Evaluation Board
Sabine M. J. M. Straus: Medicines Evaluation Board
Helga Gardarsdottir: Utrecht University
Marie L. Bruin: Utrecht University

Drug Safety, 2025, vol. 48, issue 9, No 4, 1005-1022

Abstract: Abstract Introduction Because of the novelty of advanced therapy medicinal products (ATMPs), pro-active risk management is needed post-authorisation; for example, through implementation of additional risk minimisation measures (aRMMs). Objective We described which aRMMs were introduced at marketing authorisation (MA) for ATMPs authorised in the European Union (EU), and for what safety concerns. Methods We included all ATMPs ever authorised in the EU until December 31, 2023. Data on safety concerns and aRMMs was collected from the European public assessment reports (EPARs) related to initial MA for each ATMP. Safety concerns were categorised using the Medical Dictionary for Regulatory Activities (MedDRA®) or context of use, where appropriate. Results Of the 25 included ATMPs, most (n = 23, 92.0%) were authorised with aRMMs. Of these 23 ATMPs, all (100%) had educational material for healthcare professionals. Additionally, educational material for patients/caregivers was in place for 18 (78.3%) ATMPs and a controlled distribution or controlled access programme for 16 (69.6%). Safety concerns related to ‘Long term effects’ (n = 23, 92.0%), ‘Injury, poisoning and procedural complications’ (n = 22, 88.0%), and ‘Use in special populations’ (e.g., use in pregnancy) (n = 20, 80.0%) were common among all 25 ATMPs. ATMPs often had aRMMs introduced that addressed safety concerns related to ‘Injury, poisoning and procedural complications’ (n = 19/23; 82.6%), ‘General disorders and administration site conditions’ (n = 8, 34.8%), and/or ‘Immune system disorders’ (n = 8, 34.8%). Conclusion The majority of ATMPs were authorised with aRMMs. Whilst educational materials were most prevalent, controlled distribution or controlled access programmes were also commonly introduced. For many ATMPs, aRMMs addressed risks related to ‘Injury, poisoning and procedural complications’.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-025-01550-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:48:y:2025:i:9:d:10.1007_s40264-025-01550-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-025-01550-9

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().